Quantification of cytomegalovirus (CMV) viral load by the hybrid capture assay allows for early detection of CMV disease in lung transplant recipients

Journal of Heart and Lung Transplantation

Volumn 20, Issue 9, 2001, Pages 928-934

  Bhorade, Sangeeta M ^a   Sandesara, Chirag ^a   Garrity, Edward R ^a   Vigneswaran, Wickii T ^a   Norwick, Lourdes ^a   Alkan, Serhan ^a   Husain, Aliya N ^a   McCabe, Mary A ^a   Yeldandi, Vijay ^b  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CELL NUCLEUS ANTIGEN; CIDOFOVIR; CYCLOSPORIN; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN; INTERLEUKIN 2 RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEROXIDASE; PREDNISONE; TACROLIMUS;

ADULT; ANTIBIOTIC RESISTANCE; ANTIVIRAL ACTIVITY; ARTICLE; BRONCHOSCOPY; CELL CULTURE; CLINICAL ARTICLE; COLON BIOPSY; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DIPLOIDY; DISEASE COURSE; FEMALE; FETUS; HIGH RISK POPULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERMETHOD COMPARISON; LUNG LAVAGE; LUNG TRANSPLANTATION; MORBIDITY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; QUANTITATIVE ASSAY; TRANSBRONCHIAL BIOPSY; VIRUS DETECTION; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; CELL CULTURE TECHNIQUES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CYTOSINE; DNA, VIRAL; FEMALE; GANCICLOVIR; HUMANS; ILLINOIS; IMMUNIZATION, PASSIVE; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; NUCLEIC ACID HYBRIDIZATION; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; REAGENT KITS, DIAGNOSTIC; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; SYNDROME; VIRAL LOAD;

EID: 0034841419     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-2498(01)00283-2     Document Type: Article

References (27)

1. Cytomegalovirus infection and pneumonitis: Impact after isolated lung transplantation
2. Infection after lung transplantation
3. Infectious complications in pulmonary allograft recipients
4. Infection in organ transplant recipients
5. Cytomegalovirus serologic status and postoperative infection correlated with risk of developing chronic rejection after pulmonary transplantation
6. Sequelae of cytomegalovirus pulmonary infections in lung allograft recipients
7. Cytomegalovirus infection is a risk factor for invasive aspergillosis in lung transplant recipients
8. Molecular analysis of human cytomegalovirus strains from two lung transplant recipients with the same donor
9. Correlation of cytomegalovirus DNA levels with response to antiviral therapy in cardiac and renal allograft recipients
10. Comparison of conventional and shell vial cultures for detecting cytomegalovirus infection
11. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus diseases and the duration and side effects of antiviral therapy after bone marrow transplantation
12. Direct detection of cytomegalovirus in peripheral blood leukocytes: A review of the antigenemia assay and polymerase chain reaction
13. Factors influencing detection of quantitative cytomegalovirus antigenemia
14. Monitoring for cytomegalovirus infection in organ transplant recipients: Analysis of pp65 antigen, DNA and late mRNA in peripheral blood leukocytes
15. Usefulness of DNA viral load quantification for cytomegalovirus disease monitoring in renal and pancreas/renal transplant recipients
16. Comparison of a new quantitative cytomegalovirus DNA assay with other detection methods
17. Evaluation of Murex CMV DNA hybrid capture assay for detection and quantitation of cytomegalovirus infection in patients following allogeneic stem cell transplantation
18. Evaluation of the digene hybrid capture system for detection and quantitation of human cytomegalovirus viremia in human immuno-deficiency virus-infected patients
19. Monitoring levels of human cytomegalovirus DNA in blood after liver transplantation
20. Effect of centrifuging shell vials at 3,500 × g on detection of viruses in clinical specimens
21. Quantitative analysis of cytomegalovirus viremia in lung transplant recipients
22. Quantitative detection of human cytomegalovirus DNA in lung transplant recipients
23. Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation
24. Cytomegalovirus excretion as a predictor of cytomegalovirus disease after marrow transplantation: Importance of cytomegalovirus viremia
25. Early diagnosis of human cytomegalovirus disease in transplant recipients by DNA amplification in plasma
26. Monitoring of human cytomegalovirus infections and ganciclovir treatment in heart transplant recipients by determination of viremia, antigenemia, and DNAemia
27. Preemptive treatment for the prevention of cytomegalovirus disease in lung and heart transplant recipients